secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001704292-26-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q4 total revenue $127.6M (+17% YoY); net loss narrows to $50.4M
-----------------------------------------------------------------------

- Q4 product revenue $127.1M (+17% YoY); ZEJULA $56M (+16%), XACDURO $10.7M (+225%).
- Net loss Q4 $50.4M (loss per ADS $0.46) vs $81.7M loss Q4 2024; FY loss $175.5M vs $257.1M.
- Cash $789.6M as of Dec 31, 2025; R&D expenses $61.6M Q4 (+18% YoY).
- KarXT approved in China Dec 2025; commercial launch H1 2026; NRDL renewals for VYVGART, NUZYRA, ZEJULA.
- Global pipeline: zoci (DLL3 ADC) advancing to three registration-enabling studies; ZL-1503 Phase 1 data H2 2026; ZL-1311 IND by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/0001704292-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000170429226000014/zlab-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001704292-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer